Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00901940 | Understanding the Immune Response to Meningitis Vaccines | PHASE3 | COMPLETED | 150 | — | — | Jun 1, 2009 | Oct 1, 2010 | Dec 5, 2014 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| MenACWY Plain Polysaccharide (ACWY Vax) | ACTIVE_COMPARATOR | The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax). Participants in this arm will receive 1 dose of the MenACWY plain polysaccharide (ACWY Vax) and 1 dose of the MenACWY conjugate (MenACWY). |
| MenACWY conjugate | ACTIVE_COMPARATOR | The MenACWY conjugate vaccine was licensed in the UK in March 2010, and is known as the MenACWY conjugate vaccine (Menveo). Participants in this arm will receive 2 doses of the MenACWY conjugate vaccine. |
| Name | Type | Description |
|---|---|---|
| Meningococcal (Groups A, C, Y and W-135) Conjugate | BIOLOGICAL | 2 x 0.5 mL dose |
| Meningococcal polysaccharide A, C, Y and W135 and Menveo | BIOLOGICAL | 1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo |
Inclusion Criteria: * Participant is willing and able to give informed consent for participation after the nature of the study has been explained * Male or Female, aged 18- 70 years inclusive * In good health as determined by: * Medical history * History-directed physical examination * Clini...